Laboratorio Reig Jofre Future Growth
Future criteria checks 4/6
Laboratorio Reig Jofre is forecast to grow earnings and revenue by 25.2% and 8.7% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be 7% in 3 years.
Key information
25.2%
Earnings growth rate
24.0%
EPS growth rate
| Pharmaceuticals earnings growth | 18.2% |
| Revenue growth rate | 8.7% |
| Future return on equity | 7.0% |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 408 | 17 | 9 | N/A | 1 |
| 12/31/2025 | 379 | 15 | 5 | N/A | 1 |
| 12/31/2024 | 349 | 11 | 2 | N/A | 1 |
| 9/30/2024 | 334 | 10 | N/A | N/A | N/A |
| 6/30/2024 | 334 | 9 | -3 | 16 | N/A |
| 3/31/2024 | 326 | 9 | N/A | N/A | N/A |
| 12/31/2023 | 318 | 9 | 6 | 19 | N/A |
| 9/30/2023 | 316 | 12 | N/A | N/A | N/A |
| 6/30/2023 | 298 | 10 | 6 | 18 | N/A |
| 3/31/2023 | 286 | 10 | N/A | N/A | N/A |
| 12/31/2022 | 274 | 8 | 5 | 16 | N/A |
| 9/30/2022 | 262 | 4 | N/A | N/A | N/A |
| 6/30/2022 | 256 | 5 | -6 | 5 | N/A |
| 3/31/2022 | 245 | 3 | N/A | N/A | N/A |
| 12/31/2021 | 240 | 5 | -5 | 14 | N/A |
| 9/30/2021 | 237 | 6 | N/A | N/A | N/A |
| 6/30/2021 | 234 | 5 | 9 | 22 | N/A |
| 3/31/2021 | 234 | 6 | N/A | N/A | N/A |
| 12/31/2020 | 234 | 6 | 7 | 19 | N/A |
| 9/30/2020 | 229 | 8 | N/A | N/A | N/A |
| 6/30/2020 | 229 | 6 | -15 | 14 | N/A |
| 3/31/2020 | 219 | 6 | N/A | N/A | N/A |
| 12/31/2019 | 206 | 5 | -19 | 12 | N/A |
| 9/30/2019 | 199 | 7 | N/A | N/A | N/A |
| 6/30/2019 | 188 | 9 | -10 | 16 | N/A |
| 3/31/2019 | 188 | 9 | N/A | N/A | N/A |
| 12/31/2018 | 185 | 9 | -6 | 15 | N/A |
| 9/30/2018 | 185 | 10 | N/A | N/A | N/A |
| 6/30/2018 | 179 | 9 | N/A | 14 | N/A |
| 3/31/2018 | 175 | 9 | N/A | N/A | N/A |
| 12/31/2017 | 172 | 9 | N/A | 21 | N/A |
| 9/30/2017 | 164 | 5 | N/A | N/A | N/A |
| 6/30/2017 | 164 | 7 | N/A | 8 | N/A |
| 3/31/2017 | 164 | 8 | N/A | N/A | N/A |
| 12/31/2016 | 161 | 8 | N/A | -1 | N/A |
| 9/30/2016 | 160 | 5 | N/A | N/A | N/A |
| 6/30/2016 | 159 | 5 | N/A | 8 | N/A |
| 3/31/2016 | 156 | 5 | N/A | N/A | N/A |
| 12/31/2015 | 157 | 9 | N/A | 13 | N/A |
| 12/31/2014 | 133 | 9 | N/A | -13 | N/A |
| 9/30/2014 | 122 | 9 | N/A | 12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0RB1's forecast earnings growth (25.2% per year) is above the savings rate (1.9%).
Earnings vs Market: 0RB1's earnings (25.2% per year) are forecast to grow faster than the UK market (14.4% per year).
High Growth Earnings: 0RB1's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 0RB1's revenue (8.7% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0RB1's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0RB1's Return on Equity is forecast to be low in 3 years time (7%).